Citation:Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J 2013

Citation

Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol 2013 Nov;64(5):703-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23721957.

This is a publication of ERSPC

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J 2013	For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?	Tracy Tsang	completed
Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J 2013 2	For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?	Suzanne Hughes	completed
Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J 2013 3	For men without a prostate cancer diagnosis or symptoms that might indicate prostate cancer, how many years after the start of PSA testing is the benefit of PSA testing apparent?	Tracy Tsang	completed
Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J 2013 4	For men without a prostate cancer diagnosis or symptoms that might indicate prostate cancer, how many years after the start of PSA testing is the benefit of PSA testing apparent?	Suzanne Hughes	completed

Compare quality appraisals for each clinical question

• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|]] (compare critical appraisals)
• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|]] (compare critical appraisals)
• [[Clinical question:For men without a prostate cancer diagnosis or symptoms that might indicate prostate cancer, how many years after the start of PSA testing is the benefit of PSA testing apparent?|]] (compare critical appraisals)
• [[Clinical question:For men without a prostate cancer diagnosis or symptoms that might indicate prostate cancer, how many years after the start of PSA testing is the benefit of PSA testing apparent?|]] (compare critical appraisals)

Cited by

1. ERSPC
2. Introduction
3. PSA testing and life expectancy